EU Research Funding
Horizon 2020
PMU, February 1, 2018

Anne-Emmanuelle de Crousaz, MA
Euresearch UNIL-CHUV
anne-emmanuelle.decrousaz@unil.ch
+ 41 21 693 47 50
<table>
<thead>
<tr>
<th>Project title:</th>
<th>EbolaVac</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research area:</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Partners:</td>
<td>GSK (coordinator), University of Oxford, BNITM, <strong>CHUV</strong></td>
</tr>
<tr>
<td>Duration:</td>
<td>3 years (7.10.2014 – 7.10.2017)</td>
</tr>
<tr>
<td>Project cost:</td>
<td>€19.86 M</td>
</tr>
<tr>
<td>Project funding:</td>
<td>€19.86 M</td>
</tr>
<tr>
<td>Programme:</td>
<td><strong>Horizon 2020 Societal Challenge: “Health, demographic change and well-being”</strong></td>
</tr>
<tr>
<td>Information:</td>
<td><a href="http://ebolavac.eu">http://ebolavac.eu</a></td>
</tr>
</tbody>
</table>
Content

- **What is Euresearch?**
- **Our services**
- **Funding opportunities for Health research in Horizon2020:**
  - *European Research Council (ERC)*
  - *Marie Skłodowska-Curie Actions (MSCA)*
  - *Societal Challenge «Health»*
The Euresearch network

- **Network Office in Bern (NCPs)**

- **10 Offices in the regions**
  1. Basel
  2. Bern
  3. Freiburg
  4. Geneva
  5. Lausanne
  6. Lugano
  7. Luzern
  8. Neuchatel
  9. St. Gallen
  10. Zurich

- **3 UAS Contact Points**

- **SME Contact Points**

+ **Swisscore in Brussels**

Swiss network funded by the State Secretariat for Education, Research and Innovation (SERI) to provide targeted information, hands-on advice and transnational partnering related to European R&I programmes.
Profile yourself to get information on EU R&I opportunities

https://www.euresearch.ch
What’s Horizon2020?

EU’s 2014-2020 programme for R&I (~€80 bn)
Core part of Europe 2020, Innovation Union & European Research Area

- Responding to the economic crisis to invest in future jobs and growth
- Addressing people’s concerns about their livelihoods, safety and environment
- Strengthening the EU’s global position in research, innovation and technology

http://ec.europa.eu/research/horizon2020
Why participate?

-> Whatever your reasons, your project has to fit the expectations of the European Commission.

. A new boost for jobs, growth & investment

. A connected Digital Single Market

. EU as a stronger global actor
Health Research in Horizon 2020

Collaborative R&I projects
Public-Private Partnership with big Pharma
Grants for small businesses
InnoVFIn
Loans for small & large companies

Horizon 2020

Horizon Prize
R&D - Innovation
Prizes

Public-Public Partnerships with EU Member States & beyond
Blue sky research

MORE YEARS
Better Lives

SME Instrument
Eurostars
FAST TRACK TO INNOVATION IN HORIZON 2020

EDCTP
IMI
Innovative Medicines Initiative
AAL
Research
JPND
research
Marcin Sklodowska-Curie actions
Where to find opportunities?

**HORIZON 2020 (2014-2020)**

<table>
<thead>
<tr>
<th>Excellent Science (24.4 B €)</th>
<th>Industrial Leadership (17 B €)</th>
<th>Societal Challenges (29.7 B €)</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Research Council (ERC) (13.1 B)</td>
<td>LEIT = Leadership in enabling and industrial technologies (13.5 B) - ICT - Nano, new materials - Biotechnology - Space</td>
<td>Health (7.5 B)</td>
</tr>
<tr>
<td>Future and Emerging Technologies (2.7 B)</td>
<td>Access to Risk Finance (2.9 B)</td>
<td>Food (3.9 B)</td>
</tr>
<tr>
<td>Marie Skłodowska-Curie Actions (6.1 B)</td>
<td>Innovation in SMEs/SME Instrument (0.6 B)</td>
<td>Energy (6 B)</td>
</tr>
<tr>
<td>Research Infrastructures (2.5 B)</td>
<td></td>
<td>Transport (6.3 B)</td>
</tr>
<tr>
<td></td>
<td>Spreading Excellence (0.8 B)</td>
<td>Climate (3 B)</td>
</tr>
<tr>
<td></td>
<td>Science for Society (0.5 B)</td>
<td>Inclusive Societies (1.3 B)</td>
</tr>
<tr>
<td></td>
<td>EIT (2.7 B)</td>
<td>Security (1.7 B)</td>
</tr>
<tr>
<td></td>
<td>JRC (1.9 B)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Euratom (1.6 B)</td>
<td></td>
</tr>
</tbody>
</table>

Full association of Switzerland to H2020 as of 1st January 2017
<table>
<thead>
<tr>
<th><strong>Excellent Science</strong> (24.4 B €)</th>
<th><strong>Industrial Leadership</strong> (17 B €)</th>
<th><strong>Societal Challenges</strong> (29.7 B €)</th>
</tr>
</thead>
</table>
| European Research Council (ERC) (13.1 B) | LEIT = Leadership in enabling and industrial technologies (13.5 B)  
- ICT  
- Nano, new materials  
- Biotechnology  
- Space | Health (7.5 B) |
| Future and Emerging Technologies (2.7 B) | Access to Risk Finance (2.9 B) | Food (3.9 B) |
| Marie Sklodowska-Curie Actions (6.1 B) | Innovation in SMEs/SME Instrument (0.6 B) | Energy (6 B) |
| Research Infrastructures (2.5 B) | | Transport (6.3 B) |
| | | Climate (3 B) |
| | | Inclusive Societies (1.3 B) |
| | | Security (1.7 B) |

- **Spreading Excellence** (0.8 B)
- **Science for Society** (0.5 B)
- **EIT** (2.7 B)
- **JRC** (1.9 B)
- **Euratom** (1.6 B)
ERC in a nutshell

- €13 bn (2014-2020)
- bottom-up
- all fields of science
- highly competitive (12%)
- top level peer review
- portable grants

1 Selection Criterion
- scientific excellence

1 Host Institution
- EU MS/AC

ERC
autonomous funding body since 2007

1 Project
- high risk/high gain
- ground-breaking

1 Principal Investigator (PI)
- any age
- any nationality

- Starting Grants
- Consolidator Grants
- Advanced Grants
- Proof of Concept Grants
- Synergy Grants
**ERC funding schemes**

### Starting Grant (ERC-2019-StG)
- **First PhD awarded**:
  - > 2 and ≤ 7 years prior to 1/1/19
  - (+2y for MD)
- **Max. €1.5M** / 5-y project
- **Deadline**: mid-Oct. 18
- **Time commitment of the PI**: min. 50%

### Consolidator Grant (ERC-2018-CoG)
- **First PhD awarded**:
  - > 7 and ≤ 12 years prior to 1/1/18
  - (+2y for MD)
- **Call budget**: €550M (287 grants)
- **Max €2 M** / 5-y project
- **Deadline**: 15/02/2018
- **Commitment of the PI**: min. 40%

### Advanced Grant (ERC-2018-AdG)
- **Budget**: €450M (194 grants)
- **Max. € 2.5 M** / 5-y project
- **Deadline**: 30/08/2018
- **Commitment of the PI**: min. 30%

### Synergy Grant (ERC-2019-SyG)
- **2-4 PIs** / up to 6 year projects / up to €10 M
- **Deadline**: mid-Nov. 18

### Proof of Concept Grant (ERC-2019-PoC)
- **ERC grantees only**
  - €150 000 for 18 months
  - 3 cut-off dates/year
- **StG**
  -> *for talented early-career scientists who have already produced excellent supervised work, are ready to work independently and show potential to be research leaders.*

- **CoG**
  -> *for scientists who want to consolidate their independence by establishing or strengthen an excellent research team.*

- **AdG**
  -> *for research leaders who have a track-record of outstanding research achievements in the last 10 years.*

> Information, docs & submission on the [Participant Portal](#)
Marie Skłodowska-Curie Actions (MSCA)
Marie Skłodowska-Curie Actions

Key features

- Entirely bottom-up
- Mobility as the key requirement
- Open to all domains of R&I
- Support for researchers at all stages of their career
- No age limit
- Open to researchers/staff of any nationality
## Types of MSC Actions

<table>
<thead>
<tr>
<th>Action</th>
<th>Acronym</th>
<th>Aim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual Fellowships</td>
<td>IF</td>
<td>Support for experienced researchers undertaking international and inter-sector mobility (European Fellowship / Global Fellowship)</td>
</tr>
<tr>
<td>Innovative Training Networks</td>
<td>ITN</td>
<td>Doctoral and initial training</td>
</tr>
<tr>
<td>Research and Innovation Staff Exchange</td>
<td>RISE</td>
<td>International and inter-sector cooperation through the exchange of staff (Host-driven actions)</td>
</tr>
<tr>
<td>Co-funding of programmes</td>
<td>COFUND</td>
<td>Co-funding of regional, national and international programmes: doctoral and fellowship programmes</td>
</tr>
</tbody>
</table>

**Next deadlines:**
- RISE: 18.04.18
- COFUND: 27.09.18
- IF: 12.09.18
- ITN: 16.01.19
The Societal Challenge «Health, demographic change and well-being»
Political goals of the “Societal Challenges”

- **Tackle global and societal challenges & concerns of citizens & society**
- **Address political priorities of the EU**
- **Inter-sectorial and multidisciplinary collaborative R&I**
- **Impact: European solutions for the European society / European consumers / patients (1/3 evaluation criteria)**

**Health challenges**

- Rising health & care costs (ageing, chronic diseases, increasing societal demands)
- Effects on health of environmental factors including climate change
- Threats of infectious diseases
- Health inequalities, access to health & care

**65 years:** increase from 92 million (2013) to 148 (2060)

**Chronic disease** → cause for 77 % of all deaths in Europe

**Public spending on health** 7 % of GDP (2013) to 10 % in 2050
Objective

- Improve the lifelong health and wellbeing for all - children, adults, elderly.

- Develop high-quality and economically sustainable health and care systems, and opportunities for new jobs and growth.

-> major contribution to Europe 2020
Basic participation rules

- **Collaborative projects:** at least 3 institutions of 3 different EU-Member States or EU-Associated Countries

- **SMEs are especially welcome to participate**

- **US partners can participate and get funding from the EU**
Health objectives for 2018-2020

7 priorities / 3 calls

Call 1
Better health and care, economic growth and sustainable health systems
(5 main priorities & 32 topics)

Call 2
Digital transformation in health and care
(13 topics)

Call 3
Trusted digital solutions and cybersecurity in health and care
(3 topics)

~ €1.5 billion
Health 2018-2020: 7 priorities

1. Personalised medicine

2. Innovative health and care industry

3. Infectious diseases and improving global health

4. Innovative health, and care systems - Integration of care

5. Decoding the role of the environment for health and wellbeing

6. Digital transformation in health and care

7. Trusted big data solutions and cybersecurity for health and care

Credit: EC DG RTD

1. PERSONALISED MEDICINE

- Understanding diseases & disorders
- Prevention of diseases
- Improved diagnosis
- New therapies, combinatorial therapies
- Human data storage
- Personalised medicine

POLICY DRIVERS:

CouncilconclusionsonPersonalisedMedicine
InternationalConsoritiumonPersonalisedMedicine
European Reference Network
SC1-BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities (two-stage)

Deadline: 2 October 2018 (1st stage)
16 April 2019 (2nd stage)
EU contribution: 4-6 M€

- From bench to bed of patient
- Clinical research
- Improved prevention & diagnosis
2. INNOVATIVE HEALTH AND CARE INDUSTRY

- Regenerative medicine
- New & advanced therapies
- Efficacy and regulatory science of technologies
- Development of health technology assessment methods (HTA)

POLICY DRIVERS:

Upgrading the single market
**SC1-BHC-09-2018:**
Innovative platforms for advanced therapies of the future

**Deadline:** 18 April 2018  
**EU contribution:** 12-15 M€

- Create knowledge, testing & exploitation platforms around innovative concepts for advanced therapies
- Gene delivery, immunogenicity, cell tracking...
- Technological progress in the advanced therapy field
3. INFECTIOUS DISEASES & IMPROVING GLOBAL HEALTH

- Maternal & child health
- Population & patient cohorts
- Global brain research
- Infectious diseases, earlier detection, improved prevention & treatment
- Prevention and management of hypertension and/or diabetes
- Cancer research between Europe and Latin America and the Caribbean States
- HIV, TB & HCV in patients in collaboration with Russia

POLICY DRIVERS:

Global Research Collaboration for Infectious Disease Preparedness
Global Alliance for Chronic Diseases (GACD)
A European One Health Action Plan against Antimicrobial Resistance
European & Developing Countries Clinical Trials Partnership (EDCTP)
Global Action Plan on antimicrobial resistance
SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases (two-stage)

**Deadline:** 2 October 2018 (1\textsuperscript{st} stage)
16 April 2019 (2\textsuperscript{nd} stage)

**EU contribution:** 6-10 M€

- Increased Europe's capacity to control infectious diseases
- New product development with potentially more effective, targeted treatments OR preventive measures
- Uptake into clinical practice
4. INNOVATIVE HEALTH AND CARE SYSTEMS – INTEGRATION OF CARE

- Mental health in the workplace
- Novel approaches for palliation/ end-of-life care
- Personalised medicine in health care
- HTA
- Innovation in health care

POLICY DRIVERS:

- Upgrading the single market
- Cross-border healthcare Directive
SC1-BHC-22-2019:
Mental health in the workplace (two-stage)

Deadlines: 2 October 2018 (1st stage)
16 April 2019 (2nd stage)

EU contribution: 2-4 M€

- Improved mental health and reduced sickness absence in the EU working population
- Positive impact on productivity and economic results of workplaces by improved policies and action to promote mental health
- Improved policies on mental health in the workplace based on the broader evidence base of effective interventions
5. DECODING THE ROLE OF ENVIRONMENT INCLUDING CLIMATE CHANGE, FOR HEALTH AND WELL-BEING

- New testing & screening methods to identify endocrine disrupting chemicals
- Impact of the environment on health (Human Exposome Project)
- Priorities for a European environment, climate and health research agenda

POLICY DRIVERS:

- The 7th Environment Action Programme (EAP)
- Sustainable Development Goals
- WHO Environment and Health Process (since 1989)
- The UNFCCC Paris Agreement
- REACH and EU related policies
SC1-BHC-27-2018:
New testing and screening methods to identify endocrine disrupting chemicals

Deadline: 18 April 2018
EU contribution: 4-6 M€

- New tools, methods or models to improve & harmonize screening & testing protocols for risk & hazard assessments
- Enhanced international cooperation & support for the OECD work on testing and assessing chemicals for ED activity
- Focus on regulatory needs
6. DIGITAL TRANSFORMATION IN HEALTH AND CARE

- Open service platforms for the active and ageing
- Digital transformation for the ageing
- Digital health and care services
- Big data for monitoring health status after cancer
- Personalised early risk prediction, prevention & intervention
- In silico medicine research for personalised diagnostics & therapies in cloud-based environments
- Personalised outcome based integrated care eHealth

POLICY DRIVERS:

- Connected Digital Single Market
- European Cloud Initiative
- European Free Flow of Data initiative
- Silver Economy initiative
SC1-DTH-01-2019: Big data & artificial intelligence for monitoring health status & quality of life after the cancer treatment

Deadline: 24 April 2019
EU contribution: 3-5 M€

- Mapped comprehensive big data in a manageable way by applying principles for sharing & reusability
- Create a network of knowledge
- Monitoring health status after cancer treatment
- Advanced simulation methods to study causal mechanisms
- Use patient reported outcome
7. TRUSTED DIGITAL SOLUTIONS AND CYBERSECURITY IN HEALTH AND CARE

- **Smart hospitals of the future**
- **Digital security & privacy**
- **Safe, smart & healthy living at home**
- **Cybersecurity in hospitals and care centres**
- **Cyber threats to critical infrastructures in Europe**

**POLICY DRIVERS:**

- Connected Digital Single Market
- Big Data in healthcare
- European Data Protection Regulation
**SU-TDS-02-2018:**
Toolkit for assessing and reducing cyber risks in hospitals and care centres to protect privacy/data/infrastructures

**Deadline:** 24 April 2018
**EU contribution:** 3-5 M€

- Increased patient trust & safety
- Less risk of data privacy breaches caused by cyberattacks
- Improved security of Health & Care services, data & infrastructures
H2020 project types (pillar 3)

1) **Research & Innovation Action** (RIA: 100% funding)
-> collaborative research projects with clearly defined scientific & technological objectives

2) **Innovation Action** (IA: 100 % funding for non-profit organizations: )
-> collaborative research projects closer to the market (prototyping, testing, demonstrating, piloting, …).

3) **Coordination and Support action** (CSA:100% funding)
Minimum 1 legal entity required, typical duration 12-20 months
Scope: standardization, dissemination, policy dialogues, networking activities, etc. No research.
Consortia

. At least 3 legal entities from different EU/AC
. 1 coordinating organization
. Academia, industries, SMEs, NGOs, etc.

. European diversity
. Gender aspects
. Integration of SSH
. Ethics (personal data, dual use, etc.)
. IPR, dissemination, exploitation
. Management
How to find research topics

Keywords:
- Immunology

Select the Programme
Hold the 'CTRL' key to select several programmes.
- H2020

Status:
- Forthcoming
- Open
- Closed

Sort by:
- (Planned) opening date
- Deadline
- Topic title
- Topic identifier

Topic: IMI2-2017-13-02: Genome-Environment Interactions in Inflammatory Skin Disease
Publication date: 30 November 2017

Types of action: IMI2-RIA Research and Innovation action
Deadline Model: two-stage
Opening date: 30 November 2017
Deadline: 2nd stage Deadline: 28 February 2018 17:00:00
06 September 2018 17:00:00
Time Zone: (Brussels time)
# How to find partners

<table>
<thead>
<tr>
<th>Name of the platform</th>
<th>Icon</th>
<th>Link</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Embedded Participant Portal Partner Search</strong></td>
<td>![Icon]</td>
<td><a href="http://ec.europa.eu/research/participants/portal/desktop/en/organisations/partner_search.html">http://ec.europa.eu/research/participants/portal/desktop/en/organisations/partner_search.html</a></td>
<td>Partner Search (Find and contact entities who have been involved in EU projects before)</td>
</tr>
<tr>
<td>Enterprise Europe Network</td>
<td>![Icon]</td>
<td><a href="http://www.swisseen.ch/database">www.swisseen.ch/database</a></td>
<td>Cooperation for Innovation &amp; Technology Enterprise Europe Network - Switzerland</td>
</tr>
<tr>
<td>Partnering events by HNN2.0 and EEN</td>
<td>![Icon]</td>
<td><a href="http://www.healthncp.net/">http://www.healthncp.net/</a> <a href="https://www.swisseen.ch/en/events">https://www.swisseen.ch/en/events</a></td>
<td>Partnering events</td>
</tr>
<tr>
<td>ECRIN (European Clinical Research Infrastructure Network)</td>
<td>![Icon]</td>
<td><a href="http://www.ecrin.org">www.ecrin.org</a></td>
<td>Preferred partner for clinical trials</td>
</tr>
</tbody>
</table>
Evaluation of H2020 proposals (pillar 3)

3 evaluation criteria

Excellence
• Complete description of the state-of-the-art
• Clear demonstration of innovation
• Interdisciplinarity

Impact
• Must answer each impact point mentioned in the workprogramme
• New market opportunities
• Strengthening of competitiveness and growth of companies
• Important benefits for society
• Dissemination of results
• Communication

Implementation
• Quality and effectiveness of the work plan
• Appropriateness of the management structures
• Risk and innovation management
• Complementarity of the partners
• Appropriateness of the allocation of tasks
More information?

**HEALTH**

- 2018-2020 Workprogramme
- Health detailed topic preview
- Health newcomers guide (the first 10 steps)
- Clinical studies

**MSCA (factsheets)**

- European Fellowships (EF)
- Global Fellowships (GF)
- Innovative Training Networks (ITN): European Training Networks
- RISE

**ERC**

- Self-assessment checklist (StG / CoG)
- BREXIT
Contacts

EURESEARCH UNIL-CHUV
Anne-Emmanuelle de Crousaz, MA
anne-emmanuelle.decrousaz@unil.ch (021 693 47 50)

NATIONAL CONTACT POINTS

HEALTH
Sasha Hugentobler, PhD & Agnes Szeberenyi, Msc
health@euresearch.ch (031 380 60 06/25)

ERC
Katja Wirth, PhD, Judith Zbinden, PhD & Véronique Sordet, MA
erc@euresearch.ch (031 380 60 18/16/23)

MSCA
Sibylla Martinelli, PhD & Isabelle Spühler, PhD
msca@euresearch.ch (031 380 60 11/21)
Thank you!